Alector, Inc. (ALEC) stock
ALECNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3069% below fair value
$2.54+0.09 (+3.67%)
Close on Nov 13, 2026Market cap $283.61MP/E 7.3Yield –
Alector cash
Cash and short-term investments held at the end of each period.
Alector's cash was $138.70M at Sep 30, 2026. For fiscal 2025 it was $256.02M, down 38.3% from the year before. The highest annual figure on record is $736.72M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $256.02M | -38.3% |
| FY2024 | Dec 31, 2024 | $415.24M | -24.6% |
| FY2023 | Dec 31, 2023 | $550.41M | -22.9% |
| FY2022 | Dec 31, 2022 | $714.32M | -3.0% |
| FY2021 | Dec 31, 2021 | $736.72M | +77.6% |
| FY2020 | Dec 31, 2020 | $414.78M | +17.0% |
| FY2019 | Dec 31, 2019 | $354.55M | +21.5% |
| FY2018 | Dec 31, 2018 | $291.88M | +799.4% |
| FY2017 | Dec 31, 2017 | $32.45M | -36.4% |
| FY2016 | Dec 31, 2016 | $51.04M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $138.70M | -52.4% |
| Q2 FY2026 | Jun 30, 2026 | $172.80M | -43.8% |
| Q1 FY2026 | Mar 31, 2026 | $206.52M | -41.8% |
| Q4 FY2025 | Dec 31, 2025 | $256.02M | -38.3% |
| Q3 FY2025 | Sep 30, 2025 | $291.11M | -36.3% |
| Q2 FY2025 | Jun 30, 2025 | $307.28M | -39.0% |
| Q1 FY2025 | Mar 31, 2025 | $354.55M | -36.9% |
| Q4 FY2024 | Dec 31, 2024 | $415.24M | -24.6% |
| Q3 FY2024 | Sep 30, 2024 | $457.20M | -22.4% |
| Q2 FY2024 | Jun 30, 2024 | $503.33M | -20.1% |
| Q1 FY2024 | Mar 31, 2024 | $562.08M | -16.0% |
| Q4 FY2023 | Dec 31, 2023 | $550.41M | -22.9% |
| Q3 FY2023 | Sep 30, 2023 | $588.86M | -22.3% |
| Q2 FY2023 | Jun 30, 2023 | $630.05M | -22.1% |
| Q1 FY2023 | Mar 31, 2023 | $669.33M | -22.9% |
| Q4 FY2022 | Dec 31, 2022 | $714.32M | -3.0% |
| Q3 FY2022 | Sep 30, 2022 | $758.31M | -2.5% |
| Q2 FY2022 | Jun 30, 2022 | $808.86M | +153.1% |
| Q1 FY2022 | Mar 31, 2022 | $868.57M | +139.4% |
| Q4 FY2021 | Dec 31, 2021 | $736.72M | +77.6% |
| Q3 FY2021 | Sep 30, 2021 | $777.85M | +68.5% |
| Q2 FY2021 | Jun 30, 2021 | $319.57M | -36.5% |
| Q1 FY2021 | Mar 31, 2021 | $362.74M | -33.9% |
| Q4 FY2020 | Dec 31, 2020 | $414.78M | +17.0% |
| Q3 FY2020 | Sep 30, 2020 | $461.71M | +21.0% |
| Q2 FY2020 | Jun 30, 2020 | $503.64M | +22.6% |
| Q1 FY2020 | Mar 31, 2020 | $548.54M | +25.6% |
| Q4 FY2019 | Dec 31, 2019 | $354.55M | +21.5% |
| Q3 FY2019 | Sep 30, 2019 | $381.45M | +809.5% |
| Q2 FY2019 | Jun 30, 2019 | $410.93M | +740.2% |
| Q1 FY2019 | Mar 31, 2019 | $436.60M | +1067.4% |
| Q4 FY2018 | Dec 31, 2018 | $291.88M | +799.4% |
| Q3 FY2018 | Sep 30, 2018 | $41.94M | -17.8% |
| Q2 FY2018 | Jun 30, 2018 | $48.91M | – |
| Q1 FY2018 | Mar 31, 2018 | $37.40M | – |
| Q4 FY2017 | Dec 31, 2017 | $32.45M | – |
| Q4 FY2016 | Dec 31, 2016 | $51.04M | – |
See a number that looks wrong?